At Risk Of Venous Thromboembolus — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for at risk of venous thromboembolus. 10 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
10
Active US patents
59/100
Avg vulnerability
—
Annual revenue covered

Originators in At Risk Of Venous Thromboembolus

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Portola Pharms Inc 10 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating at risk of venous thromboembolus. Each bar = one year. Y-axis scaled to peak year (4 patents).

4
26
2
28
2
30
2
31

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Bevyxxa
BETRIXABAN
 Portola Pharms Inc 10 59 — 2026-11-07

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9555023 Bevyxxa method of use 80 2026-11-07
9555023 Bevyxxa method of use 80 2026-11-07
8557852 Bevyxxa method of use 75 2028-09-08
8557852 Bevyxxa method of use 75 2028-09-08
8404724 Bevyxxa method of use 68 2031-03-29
8404724 Bevyxxa method of use 68 2031-03-29
8987463 Bevyxxa formulation 48 2030-12-28
8987463 Bevyxxa formulation 48 2030-12-28
7598276 Bevyxxa composition of matter 22 2026-11-08
7598276 Bevyxxa composition of matter 22 2026-11-08

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7598276 Bevyxxa composition of matter 22 2026-11-08
7598276 Bevyxxa composition of matter 22 2026-11-08
8987463 Bevyxxa formulation 48 2030-12-28
8987463 Bevyxxa formulation 48 2030-12-28
8404724 Bevyxxa method of use 68 2031-03-29
8404724 Bevyxxa method of use 68 2031-03-29
8557852 Bevyxxa method of use 75 2028-09-08
8557852 Bevyxxa method of use 75 2028-09-08
9555023 Bevyxxa method of use 80 2026-11-07
9555023 Bevyxxa method of use 80 2026-11-07

Related